| Literature DB >> 35207664 |
Agnieszka Pawlak1,2, Magdalena Gewartowska3, Maciej Przybylski4, Mateusz Kuffner3,5, Diana Wiligórska1, Robert Gil1, Zbigniew Król6, Malgorzata Frontczak-Baniewicz3.
Abstract
Understanding the meaning of parvovirus B19 (PB19V) in an etiology of dilated cardiomyopathy (DCM) is difficult. Viruses change the dynamics of the mitochondria by interfering with the mitochondrial process/function, causing the alteration of mitochondrial morphology. In this study, the ultrastructural changes in the mitochondria in endomyocardial biopsy (EMB) samples from patients with DCM and PB19V were determined.Entities:
Keywords: dilated cardiomyopathy; electron microscopy; mitochondria; parvovirus B19; viral infection
Year: 2022 PMID: 35207664 PMCID: PMC8880015 DOI: 10.3390/jpm12020177
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Study population.
| Parameters | Control | Patients with DCM | Patients with DCM |
|
|---|---|---|---|---|
| Male, | 7 (100) | 10 (100) | 10 (100) | 0.97 |
| Age, years | 28.0 ± 3.2 | 27.0 ± 6.3 | 28.7 ± 6.5 | 0.79 |
| NYHA Class, | ||||
| Class I | 2 (29) | 1(10) | 1 (10) | 0.14 |
| Class II | 5 (71) | 7 (70) | 6 (60) | 0.76 |
| Class III | 0 | 2 (20) | 3 (30) | 0.07 |
| Class IV | 0 | 0 | 0 | 0.98 |
| LVEF, (%) | 61.3 ± 2.3 | 23.3 ± 10.4 | 21.7 ± 6.1 | 0.01 * |
| LVEDD, (mm) | 47.7 ± 2.1 | 64.0 ± 7.2 | 62.3 ± 9.5 | 0.01 * |
| IVSDD, (mm) | 10.5 ± 0.7 | 9.3 ± 1.1 | 10.3 ± 1.1 | 0.08 |
| PWDD, (mm) | 10.0 ± 0.9 | 9.3 ± 1.1 | 10.0 ± 1.0 | 0.11 |
| NT-pro-BNP, (pg/dL) | 398.6 ± 123.2 | 609.3 ± 126.3 | 2281.6 ± 313.4 | 0.001 ** |
| CRP > 5 mg/L, | 13.9 ± 4.2 | 10.2 ± 3.9 | 33.8 ± 7.2 | 0.05 ** |
| Leukocytes > 10.000/uL, | 6.3 ± 1.4 | 7.4 ± 1.3 | 6.5 ± 1.8 | 0.12 |
| TroponinI > 0.07 ng/mL, | 19.6 ± 4.3 | 17.7 ± 3.5 | 23.3 ± 5.3 | 0.08 |
| Diseases, | ||||
| Hypertension | 0 | 0 | 0 | 0.98 |
| Hyper-lipidemia | 0 | 0 | 0 | 0.97 |
| Diabetes | 0 | 0 | 0 | 0.97 |
| Renal failure (MDRD < 40 mL/min/1.73 m2) | 0 | 0 | 0 | 0.97 |
| History of smoking | 1 (14) | 1 (10) | 2 (20) | 0.32 |
| Medication, | ||||
| ACE-I i/lub ARB | 7 (100) | 10 (100) | 10 (100) | 0.98 |
| Beta-blockers | 2 (29) | 7 (70) | 10 (100) | 0.05 * |
| Aldosteron antagonist | 0 | 3 (30) | 7 (70) | 0.08 |
| Loop diuretics | 0 | 7 (70) | 10 (100) | 0.04 |
| Statin | 0 | 7 (70) | 10 (100) | 0.04 |
| Digoxin | 0 | 0 | 33 | 0.07 |
| EMB results, | ||||
| Acute myocarditis | 0 | 0 | 0 | 0.98 |
| Borderline myocarditis | 0 | 0 | 0 | 0.98 |
| No myocarditis | 7 (100) | 10 (100) | 10 (100) | 0.98 |
| Detection of viral genome | ||||
| PB19 [no of copy] | 0 | 0 | 6670 | 0.001 ** |
Data are presented as a number of patients (n) and percentage of the population (%). DCM—dilated cardiomyopathy, EMB—endomyocardial biopsy, NYHA—New York Heart Association, LVEF—left ventricular ejection fraction, LVEDD—left ventricular end-diastolic diameter, IVSDD—intraventricular septum diastolic diameter, PWDD—posterior wall diastolic diameter, NT-pro-BNP—N-terminal pro B-type natriuretic peptide, CRP—C-reactive protein, ACE-I—angiotensin-converting-enzyme inhibitor, ARB—angiotensin receptor blocker. * p > 0.05 between control group and groups with DCM with and without PB19V, ** p > 0.05 between group with DCM and PB19V vs. control group and group with DCM without PB19V.
Figure 1Electron microscopy images. Ultrastructural features of heart biopsies from patients with EF ≥ 50% and no virus detected. (A) Loss of mitochondrial cristae marked with black arrows; disrupted outer mitochondrial membrane marked with red arrow. (B) No features of necrosis; hypertrophic endothelium marked with an asterisk.
Ultrastructural changes in the mitochondria in patients with DCM and PB19V in myocardial tissue.
| Group III | Group II | Group III |
| |
|---|---|---|---|---|
| Blurred structure of mitochondria [median (IQR)] | 1(1;1) | 1 (1;1) | 3 (2;3) | 0.0001 * |
| Increased electron density of mitochondrial matrix [median (IQR)] | 0 (0;0) | 0 (0;0) | 1 (1;1) | 0.01 * |
| Disrupted outer mitochondrial membrane [median (IQR)] | 1(1;1) | 1 (1;2) | 2 (1;2) | 0.001 ** |
| Loss of mitochondrial cristae [median (IQR)] | 1 (1;1) | 1 (1;2) | 1 (1;1) | 0.01 *** |
| Swelling of mitochondria [median (IQR)] | 0 (0;0) | 1 (1;1) | 2 (2;3) | 0.001 ** |
| Autophagy of mitochondria [median (IQR)] | 0 (0;1) | 1 (1;2) | 2 (2;3) | 0.0001 ** |
* p < 0.05 between group III vs. control group and group II; ** p < 0.05 between control group vs. group II and group II vs. group III and control group vs. group III; *** p < 0.05 between group II vs. control group and group III. The degree of mitochondrial damage was determined according to the scale: 0—no feature; 1—prevalence of the feature: 1–25%; 2—prevalence of the feature: 26–50%; 3—prevalence of the feature: 51–100%.
Figure 2Electron microscopy images. Ultrastructural features of heart biopsies from patients with EF < 50% and no virus detected. (A) A disrupted outer mitochondrial membrane marked with red arrows; (B) partial loss of mitochondrial cristae and swollen mitochondria marked with black arrows; (C) lysosomes and autophagous figures containing remnants of mitochondrial cristae marked with white arrows; (D) no features of necrosis; hypertrophic endothelium marked with an asterisk.
Figure 3Electron microscopy images. Ultrastructural features of heart biopsies from patients with EF < 50% and PB19 virus detected. (A) A blurred structure of mitochondrial membranes marked with black arrows; mitochondria showing morphological features of fission marked with frame; (B) a disrupted outer mitochondrial membrane marked with red arrows; glycogen granules in the mitochondrial matrix are visible. Mitochondria showing morphological signs of swelling marked with black arrows; (C) increased electron density of the mitochondria; (D,E) high mitophagy rate; mitophagosomes marked with white arrows; (E) sarcoplasmic reticulum with the amorphous material marked with frame and shown in the insert; (F) blood vessel with features of necrosis marked with asterisks.